title: Ecto-nucleoside triphosphate diphosphohydrolase 2 modulates local ATP-induced calcium signaling in human HaCaT keratinocytes.
abstract: Keratinocytes are the major building blocks of the human epidermis. In many physiological and pathophysiological conditions, keratinocytes release adenosine triphosphate (ATP) as an autocrine/paracrine mediator that regulates cell proliferation, differentiation, and migration. ATP receptors have been identified in various epidermal cell types; therefore, extracellular ATP homeostasis likely determines its long-term, trophic effects on skin health. We investigated the possibility that human keratinocytes express surface-located enzymes that modulate ATP concentration, as well as the corresponding receptor activation, in the pericellular microenvironment. We observed that the human keratinocyte cell line HaCaT released ATP and hydrolyzed extracellular ATP. Interestingly, ATP hydrolysis resulted in adenosine diphosphate (ADP) accumulation in the extracellular space. Pharmacological inhibition by ARL 67156 or gene silencing of the endogenous ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) isoform 2 resulted in a 25% reduction in both ATP hydrolysis and ADP formation. Using intracellular calcium as a reporter, we found that although NTPDase2 hydrolyzed ATP and generated sustainable ADP levels, only ATP contributed to increased intracellular calcium via P2Y2 receptor activation. Furthermore, knocking down NTPDase2 potentiated the nanomolar ATP-induced intracellular calcium increase, suggesting that NTPDase2 globally attenuates nucleotide concentration in the pericellular microenvironment as well as locally shields receptors in the vicinity from being activated by extracellular ATP. Our findings reveal an important role of human keratinocyte NTPDase2 in modulating nucleotide signaling in the extracellular milieu of human epidermis.
authors.affiliation: Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan.
authors.forename: Chia-Lin
authors.initials: CL
authors.lastname: Ho
authors.forename: Chih-Yung
authors.initials: CY
authors.lastname: Yang
authors.forename: Wen-Jie
authors.initials: WJ
authors.lastname: Lin
authors.forename: Chi-Hung
authors.initials: CH
authors.lastname: Lin
mesh_terms: D000244:Adenosine Diphosphate / Q000378:metabolism; D000251:Adenosine Triphosphatases / Q000378:metabolism*; D000255:Adenosine Triphosphate / Q000378:metabolism / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism; D020013:Calcium Signaling / Q000187:drug effects*; D002460:Cell Line; D002462:Cell Membrane / Q000378:metabolism; D005110:Extracellular Space / Q000187:drug effects / Q000378:metabolism; D005786:Gene Expression Regulation; D055785:Gene Knockdown Techniques; D006801:Humans; D006868:Hydrolysis; D042541:Intracellular Space / Q000187:drug effects / Q000378:metabolism; D015603:Keratinocytes / Q000187:drug effects* / Q000378:metabolism*; D058470:Receptors, Purinergic P2Y / Q000378:metabolism; D058473:Receptors, Purinergic P2Y2 / Q000235:genetics / Q000378:metabolism
chemical_list: D058470:Receptors, Purinergic P2Y; D058473:Receptors, Purinergic P2Y2; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D000251:Adenosine Triphosphatases; C027201:ectoATPase; D002118:Calcium
references.citation: Mol Pharmacol. 2005 Jan;67(1):114-22
references.pmid: 15496502
references.citation: Biochem Pharmacol. 2007 Nov 15;74(10):1524-34
references.pmid: 17727821
references.citation: Purinergic Signal. 2006 Jun;2(2):409-30
references.pmid: 18404480
references.citation: Mol Biol Cell. 2010 Mar 15;21(6):946-55
references.pmid: 20089844
references.citation: J Invest Dermatol. 2007 Mar;127(3):660-7
references.pmid: 17039239
references.citation: Exp Dermatol. 2008 Dec;17(12):1063-72
references.pmid: 19043850
references.citation: J Invest Dermatol. 2012 Mar;132(3 Pt 1):526-46
references.pmid: 22158558
references.citation: Sci Signal. 2010 Jan 12;3(104):re1
references.pmid: 20068232
references.citation: Mol Pharmacol. 2002 Sep;62(3):521-8
references.pmid: 12181428
references.citation: Purinergic Signal. 2005 Jun;1(2):193-204
references.pmid: 18404504
references.citation: J Toxicol Sci. 2011;36(6):741-50
references.pmid: 22129738
references.citation: J Invest Dermatol. 2003 Nov;121(5):1145-9
references.pmid: 14708618
references.citation: Trans Am Clin Climatol Assoc. 2007;118:199-208
references.pmid: 18528503
references.citation: Biochem J. 2004 Jun 1;380(Pt 2):329-38
references.pmid: 14967069
references.citation: Cell Death Dis. 2010;1:e9
references.pmid: 21364628
references.citation: Pharmacol Ther. 2006 Oct;112(1):264-80
references.pmid: 16780954
references.citation: Physiol Rev. 2006 Oct;86(4):1309-79
references.pmid: 17015491
references.citation: J Cell Biol. 1988 Mar;106(3):761-71
references.pmid: 2450098
references.citation: Am J Physiol. 1999 Jan;276(1):C267-78
references.pmid: 9886943
references.citation: Br J Pharmacol. 2010 Feb 1;159(3):576-85
references.pmid: 20067476
references.citation: Br J Pharmacol. 2007 Sep;152(1):141-50
references.pmid: 17603550
references.citation: Purinergic Signal. 2009 Dec;5(4):433-46
references.pmid: 19301146
references.citation: Purinergic Signal. 2012 Sep;8(3):437-502
references.pmid: 22555564
references.citation: Exp Dermatol. 2011 Jun;20(6):464-7
references.pmid: 21585554
references.citation: Biochem J. 1975 Oct;152(1):23-32
references.pmid: 1212224
references.citation: Cell Mol Life Sci. 2007 Jun;64(12):1471-83
references.pmid: 17375261
references.citation: J Invest Dermatol. 2003 Mar;120(3):440-7
references.pmid: 12603858
references.citation: Cell Tissue Res. 2009 Oct;338(1):99-106
references.pmid: 19657674
references.citation: Purinergic Signal. 2012 Sep;8(3):359-73
references.pmid: 22528679
references.citation: Eur J Pharmacol. 2007 Nov 14;573(1-3):249-52
references.pmid: 17761160
references.citation: Cardiovasc Res. 2010 Jan 1;85(1):204-13
references.pmid: 19640930
references.citation: J Pharmacol Sci. 2006 Dec;102(4):368-76
references.pmid: 17130674
references.citation: Purinergic Signal. 2006 Jun;2(2):361-70
references.pmid: 18404476
references.citation: Eur J Cell Biol. 2007 Dec;86(11-12):807-16
references.pmid: 17655967
references.citation: Pharmacol Rev. 1998 Sep;50(3):413-92
references.pmid: 9755289
references.citation: Exp Dermatol. 2011 May;20(5):401-7
references.pmid: 21355886
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):299-309
references.pmid: 11111825
references.citation: J Cutan Med Surg. 2004 Mar-Apr;8(2):90-6
references.pmid: 15129319
references.citation: Nature. 2007 Feb 22;445(7130):858-65
references.pmid: 17314972
references.citation: Pflugers Arch. 2009 Oct;458(6):1093-102
references.pmid: 19669158
references.citation: Br J Pharmacol. 1996 Dec;119(8):1628-34
references.pmid: 8982511
references.citation: Biochim Biophys Acta. 2008 May;1783(5):673-94
references.pmid: 18302942
references.citation: Pharmacol Ther. 2006 Jun;110(3):415-32
references.pmid: 16257449
references.citation: Adv Pharmacol. 2011;61:263-99
references.pmid: 21586362
references.citation: J Biol Chem. 2005 Jun 17;280(24):22986-92
references.pmid: 15799977
references.citation: Eur J Dermatol. 2008 Mar-Apr;18(2):119-27
references.pmid: 18424369
references.citation: J Biol Chem. 2005 Aug 19;280(33):29667-76
references.pmid: 15958381
references.citation: Clin Dermatol. 2012 May-Jun;30(3):257-62
references.pmid: 22507037
references.citation: Mol Pharmacol. 2003 Jul;64(1):104-12
references.pmid: 12815166
references.citation: J Invest Dermatol. 2007 Feb;127(2):362-71
references.pmid: 16946718
references.citation: FASEB J. 2007 Dec;21(14):4047-58
references.pmid: 17609252
references.citation: Br J Pharmacol. 1999 Aug;127(7):1680-6
references.pmid: 10455326
references.citation: Biochim Biophys Acta. 2009 Feb;1793(2):325-34
references.pmid: 18973777
references.citation: Eur J Pharmacol. 2006 Jul 1;540(1-3):1-9
references.pmid: 16716291